SCHEMBL1301467

SCHEMBL1301467

CCOC(=O)c1sc(-c2ccc(OC)c3oc4ccccc4c23)nc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 3/20 0.53
▸ LMNA P02545 2/20 0.47
▸ KDM4E B2RXH2 7/20 0.46
▸ ALDH1A1 P00352 5/20 0.46
▸ SMN1; SMN2 Q16637 5/20 0.46
▸ HPGD P15428 5/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ CDC7 O00311 2/20 0.45
▸ DBF4 Q9UBU7 2/20 0.45
▸ RAB9A P51151 5/20 0.43
▸ NPC1 O15118 4/20 0.43
▸ MAPT P10636 3/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1301623 0.88 PDE4B (0.56) PDE4BLMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL1301436 0.83 PDE4B (0.64) PDE4BLMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL1302124 0.79 TARBP2 (0.52) PDE4BKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL1301515 0.79 PDE4B (0.75) PDE4BMEN1KMT2A
SCHEMBL1300847 0.78 PDE4B (0.53) PDE4BLMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL10997300 0.78 LMNA (0.60) LMNAKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL1301559 0.78 PDE4B (0.47) PDE4BLMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL1302302 0.77 PDE4B (0.70) PDE4BLMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL1302356 0.74 PDE4B (0.69) PDE4BLMNAKDM4EALDH1A1RAB9A
SCHEMBL4011362 0.73 HTR2C (0.65) LMNAKDM4EALDH1A1HPGDCDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580795-B2 Heterocyclic compounds as phosphodiesterase inhibitors ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2013-11-12 — — US claimed
US-20110269753-A1 HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS ORCHID RESEARCH LABORATORIES LTD. (IN) 2011-11-03 — — US claimed
EP-2379538-A2 HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS Orchid Research Laboratories Limited (IN) 2011-10-26 — — EP claimed
WO-2010084402-A2 HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS ORCHID RESEARCH LABORATORIES LTD. (IN) 2010-07-29 — — WO claimed
US-8580795-B2 Heterocyclic compounds as phosphodiesterase inhibitors ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2013-11-12 — — US disclosed
US-8580795-B2 Heterocyclic compounds as phosphodiesterase inhibitors ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2013-11-12 — — US disclosed
US-8580795-B2 Heterocyclic compounds as phosphodiesterase inhibitors ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2013-11-12 — — US disclosed
US-20110269753-A1 HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS ORCHID RESEARCH LABORATORIES LTD. (IN) 2011-11-03 — — US disclosed
US-20110269753-A1 HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS ORCHID RESEARCH LABORATORIES LTD. (IN) 2011-11-03 — — US disclosed
US-20110269753-A1 HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS ORCHID RESEARCH LABORATORIES LTD. (IN) 2011-11-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269753-A1 HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE4B, PDE4C PDE4B 2/4885LMNA 2392/4885KDM4E 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback